Biological Evaluation of a Novel Doxorubicin−Peptide Conjugate for Targeted Delivery to EGF Receptor-Overexpressing Tumor Cells
- 2 February 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 8 (2), 375-386
- https://doi.org/10.1021/mp100243j
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapyPharmacology & Therapeutics, 2010
- Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A ReviewCurrent Drug Metabolism, 2010
- New Developments in Anthracycline-Induced CardiotoxicityCurrent Medicinal Chemistry, 2009
- Anthracycline-Induced CardiotoxicityCardiovascular & Hematological Agents in Medicinal Chemistry, 2008
- Chemotherapeutic Management of Soft Tissue SarcomaSurgical Clinics of North America, 2008
- Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers1Biology of Reproduction, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis PathwayPharmacological Reviews, 2002
- Novel Peptide Conjugates for Tumor-Specific ChemotherapyJournal of Medicinal Chemistry, 2001
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999